Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 2/20 | 0.42 |
| ▸ | ITK | Q08881 | 15/20 | 0.40 |
| ▸ | INSR | P06213 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TXK | P42681 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416855 | 1.00 | STING1 (0.42) | STING1ITKINSRMEN1KMT2A | |
| SCHEMBL6416863 | 0.89 | ALDH1A1 (0.41) | STING1ITKINSRMEN1KMT2A | |
| SCHEMBL6414426 | 0.86 | ITK (0.54) | ITKINSRTXK | |
| SCHEMBL6264379 | 0.81 | ITK (0.47) | STING1ITKINSRTXK | |
| SCHEMBL6414238 | 0.81 | ITK (0.47) | STING1ITKINSRTXK | |
| SCHEMBL6277067 | 0.80 | ITK (0.39) | ITKINSR | |
| SCHEMBL6414243 | 0.79 | ITK (0.51) | ITKINSRTXK | |
| SCHEMBL6419603 | 0.79 | ITK (0.51) | ITKINSRTXK | |
| SCHEMBL6275716 | 0.78 | ITK (0.39) | ITKINSRTXK | |
| SCHEMBL6416820 | 0.78 | ITK (0.41) | ITKINSRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | STING1 656/4885ITK 2/4885INSR 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.